Intriguingly, APT-β1 significantly enhanced the anti-tumor effect of Gefitinib (100 mg/kg/day, p.o.), a tyrosine kinase inhibitor targeting mutant EGFR, suggesting potential synergy in combination therapies to combat lung cancer. Here, EGFR is linked to neoplasm.